Autopsy report · NCT03118713

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

“Business decision due to enrollment challenges”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 8 months before it stopped.
• 33 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Astellas Pharma Korea, Inc.

Sponsor type

Industry

Conditions

Type 2 Diabetes Mellitus

Interventions

metformin; ipragliflozin; glimepiride

Participants

33

Sites

8

Countries

South Korea

Trials that died the same way

• StrataPATH™ (Precision Indications for Approved Therapies)
  “Business decision and enrollment difficulties” (86% match in meaning)
• A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
  “Business decision (no enrollment)” (81% match in meaning)
• Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
  “Enrollment Challenges” (81% match in meaning)
• Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
  “Difficulties of enrollment” (71% match in meaning)
• CorPath GRX STEMI Study
  “Low enrollment and sponsor business decision” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.